藍豐生化(002513.SZ):合同糾紛案法院准許平原中德撤訴
格隆匯12月4日丨藍豐生化(002513.SZ)公佈,公司於2019年12月4日收到《山東省平原縣人民法院民事裁定書》【(2018)魯1426民初1781號之二】。原告平原中德因合同糾紛,將公司及寧夏藍豐精細化工(統稱“被告”)訴至山東省平原縣人民法院,請求法院判令被告:1、退還第一套液下燃燒熱循環回收工業污水處理系統設備並賠償相應損失;2、要求被告支付第二套設備款433.36萬元;3、訴訟費由被告承擔。山東省平原縣人民法院於2018年7月19日立案。
目前,原告平原中德向法院提出撤訴申請。山東省平原縣人民法院准許原告平原中德撤回起訴。案件受理費20734元,由原告平原中德負擔。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.